Brind.
  1. Anthropic and Novartis are collaborating on preclinical drug discovery programs, while the rivalry between AI firms drives market focus.

Novartis CEO joins Anthropic board amid AI drug discovery push

1 report, 1 independent Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The CEO of Novartis joined the board of Anthropic on September 23, 2026. This move builds upon existing collaborations between the two companies regarding preclinical drug discovery programs. Anthropic has been expanding its capabilities, adding a Life Sciences Verification Program and training its model to direct robotic labs, while also operating a wet lab for fundamental biology research.

From redstate.com

Why it matters

Some supportBrind's analysis of the reports

The appointment reinforces the strategic link between pharmaceutical development and advanced artificial intelligence. Anthropic is pursuing preclinical work on rare diseases and other areas that traditional drugmakers may not find financially attractive. This collaboration signals a major push to integrate AI into the early stages of drug discovery.

Anthropic and Novartis are collaborating on preclinical drug discovery programs, while the rivalry between AI firms drives market attention.

From redstate.com

Who's involved

  • AnthropicAmerican artificial intelligence corporation collaborating on drug discovery
  • NovartisSwiss-American multinational pharmaceutical corporation collaborating on drug discovery

Keep exploring

Part of

Anthropic and Novartis are collaborating on preclinical drug discovery programs, while the rivalry between AI firms drives market focus. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped